X-founded biotech Stilla Technologies acquired by US Bio-Rad Labs for $225 million

Biotech Stilla Technologies, co-founded and headed by Rémi Dangla (X2005), is to be acquired by US group Bio-Rad Laboratories, the two companies and French venture capital fund Kurma Partners have announced.

Created in 2013 within the École Polytechnique, Stilla Technologies is developing a platform for genetic testing, in particular latest-generation PCR.

The capabilities of this solution enable biologists to use high-resolution tools, and researchers to extract relatively precise genomic data. The technology is capable of analyzing dozens of biomarkers at the same time, reducing genetic analysis from a week to a day. In particular, the company is developing liquid biopsy kits.

In an interview (in French) with La Jaune & La Rouge, the monthly magazine of the Association des anciens de l'X (AX), in June 2019, Rémi Dangal detailed the genesis of his entrepreneurial project, which stemmed from his doctoral thesis at the Laboratoire d'Hydrodynamique de l'X (LadHyx), under the direction of Charles Baroud.

Rémi Dangla was the winner of the Gerondeau Safran Prize in 2012. Created in memory of Jean-Louis Gerondeau (X 1962), the Prix Gerondeau - Safran aims to encourage the emergence or maturation of innovative projects led by teams from the entrepreneurial ecosystem of the École Polytechnique and the Institut Polytechnique de Paris, of which the École Polytechnique is a founding member. 

Rémi Dangla spoke at the presentation of the 12th Gerondeau-Safran Awards in 2022, underlining the importance of the Prize for its recipients.